Precision Medicine: PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer VL

Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais

Details
Jeremie Calais joins Phillip Koo on UroToday where they discuss the first annual PSMA conference hosted by UCLA and UCSF in partnership with Prostate Cancer Foundation. (PCF). The conference topics include PSMA theranostics in prostate cancer and aim to leverage early experiences and global collaborations in PSMA clinical use. It featured a multidisciplinary panel of experts from around the world,...

Nuclear Medicine Physician Discusses Career Path and Field Growth - Louise Emmett

Details
Andrea Miyahira talks with Louise Emmett who shares her unconventional journey into nuclear medicine, sparked by a contrarian spirit and a suggestion against pursuing the field. Initially specializing in nuclear cardiology in Canada, she shifted to theranostics and nuclear medicine, driven by the dynamic growth in these areas. Dr. Emmett discusses the challenges and excitement of running clinical...

ENZA-p Trial Shows Promise for Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett

Details
Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in treating early metastatic castrate-resistant prostate cancer. Patients, previously showing limited response to enzalutamide, were screened with PSMA PET and randomized to receive either enzalutamide alone or combined with lut...

The Evolution of PSMA Theranostics: A 30-Year Journey with the Prostate Cancer Foundation - Andrea Miyahira

Details
Zach Klaassen speaks with Andrea Miyahira about the Prostate Cancer Foundation’s (PCF) significant contributions to the development of PSMA theranostics in prostate cancer. Celebrating its 30th anniversary, PCF has invested over $30 million in PSMA-related research, leading to FDA-approved imaging agents and therapies like Pluvicto. Dr. Miyahira outlines the foundation's future focus, including fu...

A Historical Perspective on Radioligand Therapy and Novel Treatment Modalities in the Management of mCRPC - Neil H. Bander

Details
Neil Bander joins Charles Ryan providing a historical perspective on radioligand therapy and the history of prostate-specific membrane antigen (PSMA) for prostate cancer treatment. Dr. Bander recounts his early work in radioligand therapy and how it has developed over the past two decades before discussing the current ongoing trials highlighting a single ascending dose trial and a multiple dose tr...

PSMA PET Imaging Hot Topics - Neal Shore & Jason Efstathiou

Details
Neal Shore and Jason Efstathiou join Alicia Morgans at APCCC 2022 to discuss the current landscape in PSMA PET imaging. Drs Shore and Efstathiou share their thoughts on the agents they are using and the impacts of these new developments in imaging on staging and prognostication. Biographies: Jason Efstathiou, MD, Radiation Oncologist Professor of Radiation Oncology, Harvard Medical School, Vice-Ch...

Imaging and PET Analysis as a Prognostic Tool for Lu-PSMA-617 Treatment in Patients with mCRPC - Phillip H. Kuo

Details
Phillip Kuo joins Alicia Morgans to discuss recent findings in a VISION sub-study. Dr. Kuo explains how this post-hoc exploratory analysis of the PSMA PET scans that were done for the VISION trial resulted in a better understanding of which patients are likely to respond better to treatment with lutetium-PSMA-617. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of Medical Imaging, Medicine and B...

Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne

Details
Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...

Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris

Details
Michael Morris joins Alicia Morgans to discuss the clinical implementation of Pluvicto™ (177Lu-PSMA-617) in a way that ensures equity to all patients, regardless of the many factors that could disrupt access. They discuss equity of distribution to all those patients who need it and the availability of PSMA PET scans. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourin...

Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor

Details
Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discu...